| 1. |
- Siegbahn, Agneta, et al.
(författare)
-
Coagulation and fibrinolysis during the normal menstrual cycle
- 1989
-
Ingår i: Upsala Journal of Medical Sciences. - 0300-9734 .- 2000-1967. ; 94:2, s. 137-152
-
Tidskriftsartikel (refereegranskat)abstract
- Thirteen healthy women (age 24-44 yrs) were studied during their menstrual cycle. Samples were taken 2-3 times weekly for six consecutive weeks. Plasma concentrations of oestradiol and progesterone were determined in each blood sample and only women found to be ovulatory were included. From the hormone data the cycles were divided in five phases (early follicular phase, late follicular phase, early luteal phase, late luteal phase and menstrual period). The samples for the coagulation and fibrinolysis assays as well as the venous occlusion (20 min) tests were drawn or performed between 8-9 a m after fasting for 8 hrs. The fibrinogen F VIII:C and AT III were assayed and did not show any variations through the study period. Neither were any differences found in platelet counts, platelet mean volumes or platelet function measured as platelet adhesion and plasma beta-thromboglobulin. The fibrinolytic activity after venous occlusion decreased slightly during the late luteal phase (phase 4) as compared with the other phases. Large individual differences were, however, seen and no statistically significant differences between the five different phases were found. The plasminogen activator inhibitor (PAI-1) varied during the cycle but in most individuals within the normal range. In 7/13 women substantial fluctuations of the fibrinolytic activities during the cycle were seen. Four women had a significant fall of the fibrinolytic activity after venous occlusion during the late luteal phase (phase 4) and 3 others during the menstrual phase (phase 5). No co-variation between the fibrinolytic activities and PAI-1 was found. Multiple regression analysis showed a co-variation between fibrinolytic activities and progesterone.
|
|
| 2. |
|
|
| 3. |
- Siegbahn, Agneta, et al.
(författare)
-
Production of chemokinetic inhibitory factor (CIF) by normal blood and spleen B lymphocytes
- 1986
-
Ingår i: Leukemia Research. - 0145-2126 .- 1873-5835. ; 10:2, s. 179-186
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- We have recently reported the partial purification and characterization of of a new lymphokine, the heat-labile chemokinetic inhibitory factor (CIF) which inhibits neutrophil movement. We have also shown that this lymphokine is produced and secreted by cultured B-chronic lymphocytic leukaemia (CLL) cells in vitro. The present study shows that highly purified resting normal B lymphocytes from blood and spleen have the capacity to produce CIF spontaneously. After activation with anti-IgM or EBV-infection the lymphocytes produced a number of other factors, heat-stable chemokinetic inhibitory factors and heat-labile chemokinetic enhancing factors. Supernatants from a collection of human B-cell lines representing different stages of B-cell differentiation were also investigated. None of these cell lines produced CIF. The present results show that the production of CIF is not restricted to the malignant B-CLL cell but is also produced by a subset of normal blood and spleen B cells.
|
|
| 4. |
- Siegbahn, Agneta, et al.
(författare)
-
Specific binding of B-CLL cell-derived chemokinetic inhibitory factor (CIF) to human polymorphonuclear leukocytes
- 1987
-
Ingår i: European Journal of Haematology. - 0902-4441 .- 1600-0609. ; 39:2, s. 172-179
-
Tidskriftsartikel (refereegranskat)abstract
- The chemokinetic inhibitory factor (CIF) is a recently described B-cell derived lymphokine that mediates a chemokinetic inhibitory effect on human polymorphonuclear leukocyte (PMN) migration. In the present report the interaction of CIF with the neutrophil plasma membrane was studied. Normal human peripheral blood neutrophils and purified neutrophil plasma membranes selectively removed biologic activity from CIF-containing concentrates obtained during the purification procedure from conditioned medium. Removal was obtained at both 4 degrees C and 37 degrees C. Furthermore, HL-60 cells treated with dimethyl sulfoxide removed CIF activity (granulocyte-like cells) but HL-60 cells treated with 12-O-tetradecanoylphorbol-13-acetate (macrophage-like cells) did not. Purified human blood monocytes, cells from the macrophage-like U-937 cell line and cells from the basophilic leukemia cell line KU-812 did not remove CIF. These studies suggest that neutrophils express specific binding sites for CIF-activity.
|
|
| 5. |
- Siegbahn, Agneta, et al.
(författare)
-
The chemokinetic inhibitory factor (CIF) in serum of CLL patients : correlation with infection propensity and disease activity
- 1985
-
Ingår i: Scandinavian journal of haematology. - 0036-553X. ; 35:1, s. 80-87
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- We have recently described the partial purification and characterization of a neutrophil migration inhibitory activity present in serum from patients with chronic lymphocytic leukaemia (CLL). This new lymphokine, the chemokinetic inhibitory factor (CIF), is produced by B-CLL cells. It is a heat-labile glycoprotein of an approximate molecular weight (m. w.) of 30000. In this extended investigation 64/89 CLL-patients had CIF in their serum. CLL serum diluted to a concentration of 0.02% gave significantly decreased chemokinetic activity, suggesting that CIF is potent at very low concentrations. 31/89 patients had increased infection propensity. Significantly more patients with CIF in serum had infections compared to the group with normal susceptibility to infections. The combination of low Ig levels and CIF in serum discriminated even better between the infection-prone and non-infection-prone patients. CIF in serum was not correlated to tumour cell mass - estimated by Rai clinical staging - tumour progression or deoxythymidine kinase, S-TK, an enzyme that may reflect proliferating cells. The existence of this new lymphokine in serum seems to contribute to the increased susceptibility to infections seen in CLL patients.
|
|
| 6. |
- Siegbahn, Agneta, et al.
(författare)
-
The chemokinetic inhibitory factor derived from chronic lymphocytic leukaemia cells : Partial purification and characterization of a new lymphokine
- 1986
-
Ingår i: Scandinavian Journal of Immunology. - 0300-9475 .- 1365-3083. ; 23:1, s. 15-23
-
Tidskriftsartikel (refereegranskat)abstract
- We have recently described a heat-labile and cell-directed neutrophil migration inhibitory activity that is present in serum from patients with chronic lymphocytic leukaemia (CLL). The inhibitory activity is produced and secreted by CLL cells in vitro. In the present study the inhibitory activity was partially purified from short-term cultures of monoclonal leukaemic B-CLL cells. On gel filtration the calculated molecular weight was apparently 30,000. By anion exchange chromatography, the inhibitory factor was recovered in the fractions that eluted with 0.3 mol/l NaCl. The active material applied to preparative agarose gel electrophoresis migrated towards the anode. The inhibitory factor was totally destroyed by trypsin. In addition it bound to concanavalin A-Sepharose. These properties indicate that the inhibitory factor is a glycoprotein. Antibodies against the isolated inhibitory factor were raised in rabbits. CLL serum was separated by means of gel filtration and the inhibitory activity was recovered in the pool with a molecular weight of approximately 30,000. The activity was completely neutralized by the antibodies raised against the CLL-cell-derived inhibitor, indicating the similarity between this and the serum-derived inhibitor. We have shown the existence of a new lymphokine, derived from B-CLL cells, in serum from patients with CLL.
|
|
